Sterigenics International LLC has acquired Toxikon Europe N.V., the European division of Toxikon Corp., a Bedford, MA-based preclinical CRO. Financial terms were not disclosed. 
 
Toxikon Europe provides analytical, material characterization and microbiological services to the pharma, biopharma and medical device industries. The company also offers extractables and leachables (E&L) testing expertise and database to help enhance flexibility and speed to market.
 
This acquisition expands Sterigenics Nelson Labs business, which will now offer Toxikon Europe’s E&L capabilities, in addition to its microbiological services, to Toxikon Europe’s customers. 
 
As part of this deal, Nelson Labs and Toxikon USA will enter into a long-term supply arrangement under which Nelson Labs will outsource in-vivo biocompatibility to Toxikon USA.
 
“Toxikon Europe’s geographic foothold and expert analytical testing platform enable our global expansion and ability to provide significantly greater value to customers,” said Michael B. Petras Jr., chief executive officer of Sterigenics International. “We are excited to welcome a strong management team, with over 150 years of aggregate industry experience, and the highly trained Toxikon Europe employees to our company.”
  
“The acquisition of Toxikon Europe and our ongoing partnership with Toxikon USA support our strategy to offer greater breadth of services to meet the demands of our rapidly growing, global customer base,” said Jeff Nelson, president of Nelson Labs. “We are now able to serve the pharmaceutical and medical device industries continuously from the early stages of product development through manufacturing, sterilization, and quality assurance testing.”